My Ultimate Sign-in System Made Me Invincible Chapter 567 Adjustments Being Made

Over the subsequent days, the progress of the initial group of volunteers unfolded, captivating the attention of the entire world.

By the fourth day, Diego's legs had regenerated to his ankles. This remarkable transformation was broadcast live to over six billion people, who had integrated the stream into their daily routines—checking it in the morning, watching throughout the afternoon, and even sleeping with it on, only to wake and find it still running.

The comment section had evolved into a unique community. Individuals who had followed the stream since the very first injection became recognizable names, often tagging each other when significant events occurred. They developed a shared language for an unprecedented situation.

Yet, after four days, the existing vocabulary still felt inadequate.

Maya's recovery took a different path. She was now walking, albeit cautiously, with a nurse nearby and her mother always within reach. While not yet the fully ambulatory state she would eventually achieve, she was walking. Her own legs, supporting her own weight, carried her across a room on the moon.

Rosa observed every step in silent contemplation.

***

The pharmaceutical industry had been in decline for three days.

What began as market volatility escalated into a significant downturn by the second day. This shift occurred when the tissue regeneration on Diego's legs became undeniable on the livestream, and the viewer count surged past 6.7 billion, remaining at that elevated level.

By the fourth day, the situation was no longer mere volatility but a sustained downward trend.

Within a boardroom on the forty-seventh floor of a Manhattan skyscraper, seven individuals sat around a table, their gaze fixed on a screen displaying a prominently negative figure.

The CFO of a major U.S. pharmaceutical company had been scrutinizing this number for forty minutes. She had encountered negative figures before, but this was different.

The numbers had been bad when Nova Technologies first unveiled their product, but not this dire.

The critical difference was that previously, it was merely speculation from a highly advanced company. Now, the clinical trial and the live broadcast had rendered it an irrefutable reality.

And she saw no viable path to reversing the current situation.

The Head of Investor Relations glanced at the screen. "The trial has not concluded. We lack final data. We haven't submitted for regulatory approval, nor have we received it. There is no product on the market."

"There are six billion people watching a twenty-two-year-old from Honduras regrow his legs on the moon," the CFO countered. "THAT is the regulatory filing."

Silence filled the room.

"The market isn't waiting for approval," she continued. "It's observing the livestream and posing a question that transcends our product pipeline. It's asking whether there exists a category of human disease that nanite technology cannot address. And the candid answer—based on publicly available information—is that we are unaware of any such category."

The Head of Strategic Planning, who had remained largely silent since the meeting commenced, looked up from the table. "Our oncology pipeline."

"Is worth less today than it was last week," she stated. "Not because of any change in our research, but because the upper limit of medical capabilities has shifted, and the market is recalibrating accordingly." She paused. "This is not a typical market correction. This is the market acknowledging a fundamental shift in assumptions."

No one disputed her assessment.

The figure on the screen had remained static for the three minutes since she last checked it. And if it were to change, it would undoubtedly be downward.

***

In Washington, efforts were underway to manage the situation on multiple fronts.

The public stance remained consistent with the administration's prior statement—support for the trial, acknowledgment of American medical professionals' involvement, and adherence to the narrative of historic collaboration. This was the appropriate stance and would be maintained regardless of market fluctuations.

The private discussions, however, were far more complex.

Patricia Yuen had been engaged in back-to-back meetings since early morning. The Treasury Department sought clarity on market stability within the healthcare sector. The FDA had questions regarding regulatory precedents. The Department of Commerce was concerned about the implications of such advanced technology on trade relationships previously built on now-obsolete assumptions.

She provided answers where possible and deferred questions she couldn't address. As the day concluded, she sat in her office, the livestream playing quietly on a secondary screen.

On the screen, Diego was asleep.

She watched him for a time.

The number the market was producing, she mused, was actually rather truthful, merely an adjustment. The market was examining the foundations of established medicine and re-evaluating their stability.

These foundations proved unstable, a fact evident to anyone observing the livestream for over an hour.

The concern for her office wasn't the market itself; the market would eventually find its balance. The true concern lay with the surrounding infrastructure that had been built upon the previous equilibrium—the regulatory frameworks, the approval processes, and the institutional ties between the government and pharmaceutical companies that had dictated health policy for decades.

This infrastructure had been designed for a reality where such advancements were deemed impossible.

The world underwent a transformation on a Tuesday, but the infrastructure remained unchanged.

She gazed at the screen. Diego's leg was visible within the frame, the tissue now seamlessly connected from ankle to foot, with the meticulous work continuing beneath the surface.

She picked up her pen and began to write.

***

In Tokyo, the Nikkei's healthcare index mirrored the movements already observed in the American and European markets.

In London, several prominent pharmaceutical companies released statements—carefully worded, measured, and professionally managed—acknowledging the trial's significance while underscoring the necessity of stringent regulatory procedures.

These statements were extensively read and widely interpreted as the corporate equivalent of a person composing their features before a photograph was taken.

In Beijing, the State Council's internal assessments were two days ahead of any public commentary, and the conclusions drawn were remarkably similar to those resting on Patricia Yuen's desk in Washington.

The world, constructed upon a specific set of assumptions regarding the capabilities and limitations of medicine, was now adapting to a new paradigm.

This adjustment, thus far, had been orderly. Most analysts believed it would remain so, provided the transition was gradual.

The livestream had been active for four days, and the trial was expected to continue for weeks, possibly months.

This indicated that the adjustment was unlikely to be a gradual one.